Lisa Seitz
About Lisa Seitz
Lisa Seitz is the Senior Director of Translational Science at Arcus Biosciences, where she has worked since 2020. She has extensive experience in biomarker analysis and clinical dose selection, with a background in microbiology and biology from Indiana University Bloomington.
Current Role at Arcus Biosciences
Lisa Seitz serves as the Senior Director of Translational Science at Arcus Biosciences, a position she has held since 2020. In this role, she oversees the translational science initiatives, focusing on the analysis of clinical samples and the development of assays that establish pharmacokinetic and pharmacodynamic relationships. Her work is integral to clinical dose selection processes.
Previous Experience at Arcus Biosciences
Lisa Seitz previously worked at Arcus Biosciences in various roles. She served as Principal Investigator from 2017 to 2018 and later as Director from 2019 to 2020. During her time at the company, she contributed to the development of clinical strategies and managed projects related to biomarker analysis.
Educational Background
Lisa Seitz studied at Indiana University Bloomington, where she earned a Master’s degree in Microbiology from 1994 to 1997. She also completed her Bachelor of Science in Biology at the same institution from 1988 to 1991. This educational foundation has equipped her with a strong background in the life sciences.
Career History and Expertise
Lisa Seitz has extensive experience in the biotechnology and pharmaceutical industries. She has held positions at notable companies such as Amgen, where she worked as Senior Associate Scientist and Associate Scientist, and Eli Lilly and Company as an Associate Biochemist. Her expertise includes flow cytometry, immunology, molecular biology, and genetics, with a focus on biomarker analysis and clinical project management.
Publications and Contributions
Lisa Seitz has a track record of publications in scientific journals, contributing to the advancement of knowledge in her field. She has played a key role in multiple Investigational New Drug (IND) filings and has been a vital member of project teams that have successfully advanced numerous small molecules into clinical studies.